An adherent subline of a unique small-cell lung cancer cell line downregulates antigens of the neural cell adhesion molecule.

Por Doyle, L A, Borges, M, Hussain, A, Elias, A, Tomiyasu, T
Publicado em 1990

Modulation of neuroendocrine surface antigens in oncogene-activated small cell lung cancer lines.

Por Doyle, L. A., Mabry, M., Stahel, R. A., Waibel, R., Goldstein, L. H.
Publicado em 1991

Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma

Por Prado, C M M, Bekaii-Saab, T, Doyle, L A, Shrestha, S, Ghosh, S, Baracos, V E, Sawyer, M B
Publicado em 2012

Expression of a 95 kDa membrane protein is associated with low daunorubicin accumulation in leukaemic blast cells.

Por Doyle, L. A., Ross, D. D., Sridhara, R., Fojo, A. T., Kaufmann, S. H., Lee, E. J., Schiffer, C. A.
Publicado em 1995

An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein.

Por Doyle, L. A., Ross, D. D., Ordonez, J. V., Yang, W., Gao, Y., Tong, Y., Belani, C. P., Gutheil, J. C.
Publicado em 1995

Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma

Por Naing, A, LoRusso, P, Fu, S, Hong, D, Chen, H X, Doyle, L A, Phan, A T, Habra, M A, Kurzrock, R
Publicado em 2013

A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours

Por Wilky, B A, Rudek, M A, Ahmed, S, Laheru, D A, Cosgrove, D, Donehower, R C, Nelkin, B, Ball, D, Doyle, L A, Chen, H, Ye, X, Bigley, G, Womack, C, Azad, N S
Publicado no Br J Cancer (2015)

Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors

Por Koczywas, M, Frankel, P H, Synold, T W, Lenz, H-J, Mortimer, J E, El-Khoueiry, A B, Gandara, D R, Cristea, M C, Chung, V M, Lim, D, Reckamp, K L, Lau, D H, Doyle, L A, Ruel, C, Carroll, M I, Newman, E M
Publicado no Br J Cancer (2014)

Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer(†)

Por Carter, C. A., Rajan, A., Keen, C., Szabo, E., Khozin, S., Thomas, A., Brzezniak, C., Guha, U., Doyle, L. A., Steinberg, S. M., Xi, L., Raffeld, M., Tomita, Y., Lee, M. J., Lee, S., Trepel, J. B., Reckamp, K. L., Koehler, S., Gitlitz, B., Salgia, R., Gandara, D., Vokes, E., Giaccone, G.
Publicado no Ann Oncol (2016)